CM Gerrits, M Bhattacharya, S Manthena, … - … and drug safety, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets. In
this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the ... Cited by 62 - Related articles - BL Direct - All 4 versions
T Mazzone, A Chait, J Plutzky - The Lancet, 2008 - Elsevier Individuals with type 2 diabetes mellitus have increased cardiovascular disease risk compared with
those without diabetes. Treatment of the residual risk, other than blood pressure and
LDL-cholesterol control, remains ... Cited by 37 - Related articles - All 11 versions
HE Bays, JM Gonzlez-Campoy, GA Bray, AE … - Expert Review of …, 2008 - ingentaconnect.com When caloric intake exceeds caloric expenditure, the positive caloric balance and storage of energy
in adipose tissue often causes adipocyte hypertrophy and visceral adipose tissue accumulation. These
pathogenic anatomic abnormalities ... Cited by 27 - Related articles - All 4 versions
CA Reasner - Journal of Cardiovascular Pharmacology, 2008 - journals.lww.com Abstract: Insulin resistance syndrome is characterized by hyper- glycemia, atherogenic dyslipidemia,
hypertension, and abdominal obesity. Hyperglycemia is the major risk factor for microvascular
complications in type 2 diabetes. ... Cited by 9 - Related articles - All 4 versions
- ►jbc.org I Pagel-Langenickel, J Bao, JJ Joseph, DR … - Journal of Biological …, 2008 - ASBMB The pathophysiology underlying mitochondrial dysfunction in insulin-resistant skeletal muscle is
incompletely characterized. To further delineate this we investigated the interaction between
insulin signaling, mitochondrial ... Cited by 9 - Related articles - All 5 versions
RA Ajjan, PJ Grant - Expert Opin. Drug Saf., 2008 - informahealthcare.com Background: Thiazolidinediones (rosiglitazone, pioglitazone) influence insulin sensitivity and are
used for the treatment of Type 2 diabetes. Rosiglitazone achieves sustained improvements in
glycaemic control, whilst having ... Cited by 6 - Related articles - All 7 versions
R Cubbon, M Kahn, MT Kearney - International journal of clinical …, 2008 - interscience.wiley.com Patients with type 2 diabetes mellitus (T2DM) and prediabetes have a substantially greater risk of
developing cardiovascular (CV) disease than the general population. This increased risk of CV
disease is due to a complex cluster ... Cited by 5 - Related articles - BL Direct - All 4 versions
SA Doggrell - Expert Opin. Pharmacother., 2008 - informahealthcare.com The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment of Type 2 diabetes
(T2DM). Both have been shown to decrease glycated haemoglobin levels, fasting plasma glucose,
insulin, and free fatty acids ... Cited by 5 - Related articles - BL Direct - All 7 versions
RB Goldberg - Current Opinion in Endocrinology, Diabetes and …, 2007 - journals.lww.com Recent findings: The thiazolidinedione class improves endothelial vasomotion, inhibits inflammatory
and procoagulant processes and has powerful antiproliferative and antioxidant effects.
Experimentally these agents retard ... Cited by 4 - Related articles - BL Direct - All 4 versions
